<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a833/9207649/015911591427/ActaDV-100-15-5837-g001.jpg"/> </div> <div class="text-side"> <h1>Vascular Endothelial Growth Factor Receptor-3 Expression Predicts Sentinel Node Status in Primary Cutaneous Melanoma.</h1> <p>Vascular endothelial growth factor-A (VEGF), VEGFR-2, and VEGFR-3 expression in different primary cutaneous melanomas. (a–c) Nodular melanoma showing strong VEGF expression by a subset of tumour cells and in the epidermis overlying the melanoma (a) Haematoxylin-eosin staining (H&amp;E), original magnification ×25, (b, c) VEGF staining, original magnification ×25 and ×50. (d–f) Superficial spreading melanoma showing strong VEGF expression in the epithelium and by approximately 50% of the tumour cells, but no VEGFR-2 expression; (d) H&amp;E, original magnification ×50, (e) VEGF staining, original magnification ×50, (f) VEGFR-2 staining, original magnification ×50. (g, h) Nodular melanoma showing strong VEGFR-3 expression; (g) H&amp;E, original magnification ×25, (h) VEGFR-3 staining, original magnification ×50.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32618346/" target="_blank">32618346</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>